TY - JOUR
T1 - Predictors of vision-related quality of life in patients with macular oedema receiving intra-vitreal anti-VEGF treatment
AU - Rausch-Koster, Petra T.
AU - Rennert, Katharina N.
AU - Heymans, Martijn W.
AU - Verbraak, Frank D.
AU - van Rens, Ger H. M. B.
AU - van Nispen, Ruth M. A.
N1 - Funding Information: Funding for this investigator‐initiated research was provided by Bayer Healthcare, Mijdrecht (Fellowship name/number: IMP20112/VUmc PROM). The sponsor or funding organization had no role in the design or conduct of this research. Publisher Copyright: © 2022 The Authors. Ophthalmic and Physiological Optics published by John Wiley & Sons Ltd on behalf of College of Optometrists.
PY - 2022/7
Y1 - 2022/7
N2 - Purpose: To determine which demographic and clinical characteristics are predictive of vision-related quality of life (VrQoL) and quality of life (QoL) in patients with macular oedema receiving intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Methods: Vision-related quality of life (VrQoL) and quality of life (QoL) were measured in 712 patients with retinal exudative disease receiving anti-VEGF treatment at baseline, 6 and 12 months. VrQoL was measured using an item-response theory based 47-question item bank (EyeQ), whereas QoL was measured using the EuroQol Five Dimensions (EQ-5D) questionnaire. The EQ-5D score was dichotomized into a perfect score of 1 and a suboptimal score of <1. Demographic and clinical patient characteristics were considered as possible predictors of (Vr)QoL. Prediction models for (Vr)QoL were created with linear mixed models and generalised estimating equations, using a forward selection procedure. Results: A worse VrQoL was predicted by poorer LogMAR visual acuity of the better eye, female sex, single civil status, older age, longer length of anti-VEGF treatment at baseline and the presence of non-ocular and ocular comorbidities. Suboptimal EQ-5D scores were predicted by poorer LogMAR visual acuity of the better eye, female sex, single civil status, older age, the presence of non-ocular comorbidities and a lower educational background. Conclusions: Along with visual acuity of the better eye, which is the main factor used in clinical decision making, other patient characteristics should also be considered for the risk assessment of (Vr)QoL, such as sex, age, civil status, comorbidities and length of anti-VEGF treatment.
AB - Purpose: To determine which demographic and clinical characteristics are predictive of vision-related quality of life (VrQoL) and quality of life (QoL) in patients with macular oedema receiving intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Methods: Vision-related quality of life (VrQoL) and quality of life (QoL) were measured in 712 patients with retinal exudative disease receiving anti-VEGF treatment at baseline, 6 and 12 months. VrQoL was measured using an item-response theory based 47-question item bank (EyeQ), whereas QoL was measured using the EuroQol Five Dimensions (EQ-5D) questionnaire. The EQ-5D score was dichotomized into a perfect score of 1 and a suboptimal score of <1. Demographic and clinical patient characteristics were considered as possible predictors of (Vr)QoL. Prediction models for (Vr)QoL were created with linear mixed models and generalised estimating equations, using a forward selection procedure. Results: A worse VrQoL was predicted by poorer LogMAR visual acuity of the better eye, female sex, single civil status, older age, longer length of anti-VEGF treatment at baseline and the presence of non-ocular and ocular comorbidities. Suboptimal EQ-5D scores were predicted by poorer LogMAR visual acuity of the better eye, female sex, single civil status, older age, the presence of non-ocular comorbidities and a lower educational background. Conclusions: Along with visual acuity of the better eye, which is the main factor used in clinical decision making, other patient characteristics should also be considered for the risk assessment of (Vr)QoL, such as sex, age, civil status, comorbidities and length of anti-VEGF treatment.
KW - Quality of Life
KW - Vision-related Quality of Life
KW - intravitreal anti-vascular endothelial growth factor (anti-VEGF)
KW - macular oedema
UR - http://www.scopus.com/inward/record.url?scp=85127433085&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/opo.12984
DO - https://doi.org/10.1111/opo.12984
M3 - Article
C2 - 35366334
SN - 0275-5408
VL - 42
SP - 849
EP - 857
JO - Ophthalmic and Physiological Optics
JF - Ophthalmic and Physiological Optics
IS - 4
ER -